RT Conference Proceedings
T1 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
A1 Faivre-Finn, C.
A1 Vicente, D.
A1 Kurata, T.
A1 Planchard, D.
A1 Paz-Ares, L.
A1 Vansteenkiste, J. F.
A1 Spigel, D. R.
A1 Garassino, M. C.
A1 Reck, M.
A1 Senan, S.
A1 Naidoo, J.
A1 Rimner, A.
A1 Wu, Y-L.
A1 Gray, J. E.
A1 Ozguroglu, M.
A1 Lee, K. H.
A1 Newton, M.
A1 Wang, L.
A1 Thiyagarajah, P.
A1 Antonia, S. J.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27553
UL https://hdl.handle.net/10668/27553
LA en
DS RISalud
RD Apr 19, 2025